Linsitinib (OSI-906)

Catalog No.S1091

Linsitinib (OSI-906) Chemical Structure

Molecular Weight(MW): 421.49

Linsitinib (OSI-906) is a selective inhibitor of IGF-1R with IC50 of 35 nM in cell-free assays; modestly potent to InsR with IC50 of 75 nM, and no activity towards Abl, ALK, BTK, EGFR, FGFR1/2, PKA etc. Phase 3.

Size Price Stock Quantity  
In DMSO USD 190 In stock
USD 170 In stock
USD 270 In stock
USD 720 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 76 Publications

Purity & Quality Control

Choose Selective IGF-1R Inhibitors

Biological Activity

Description Linsitinib (OSI-906) is a selective inhibitor of IGF-1R with IC50 of 35 nM in cell-free assays; modestly potent to InsR with IC50 of 75 nM, and no activity towards Abl, ALK, BTK, EGFR, FGFR1/2, PKA etc. Phase 3.
Targets
IGF-1R [1]
(Cell-free assay)
Insulin Receptor [1]
(Cell-free assay)
IRR [1]
(Cell-free assay)
35 nM 75 nM 75 nM
In vitro

OSI-906 inhibits IGF-1R autophosphorylation and activation of the downstream signaling proteins Akt, ERK1/2 and S6 kinase with IC50 of 0.028 to 0.13 μM. OSI-906 enables an intermediate conformation of the target protein through interactions with the C-helix. OSI-906 displays favorable metabolic stability in liver microsomes. OSI-906 fully inhibits both IR and IGF-1R phosphorylation at a concentration of 1 μM. OSI-906 inhibits proliferation of several tumor cell lines including non-small-cell lung cancer and colorectal cancer (CRC) tumor cell line with EC50 of 0.021 to 0.810 μM. [1]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
A4-Fuk NWGyNI9PT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3v2TGlEPTB;MD6wNlgxPiEQvF2= MlG5V2FPT0WU
KS-1 M3rWcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF22VVlKSzVyPUCuNFM5OzVizszN NInXVm9USU6JRWK=
TE-11 NW\DSmYyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWLjZlB7UUN3ME2wMlA4QDJ{IN88US=> MUHTRW5ITVJ?
EW-1 NEnCfHFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHn2S5lKSzVyPUCuNFg2QDVizszN M2P0bnNCVkeHUh?=
HMV-II NEC5bIpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmS5TWM2OD1yLkC4PFQ3KM7:TR?= NUPpZlZ{W0GQR1XS
COLO-205 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWTJR|UxRTBwMUC0OVQh|ryP MlqzV2FPT0WU
ES1 M4Lubmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NY[wb|duUUN3ME2wMlExPjl4IN88US=> MXTTRW5ITVJ?
GDM-1 M1;hT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml;UTWM2OD1yLkGzOlczKM7:TR?= M1HWb3NCVkeHUh?=
ML-2 Ml\2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnS0TWM2OD1yLkG1PFk3KM7:TR?= NVLjXlZmW0GQR1XS
Saos-2 MkPiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUHJR|UxRTBwMU[1NlYh|ryP NECxNJFUSU6JRWK=
NCI-H1355 MlnRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnnVTWM2OD1yLkG4NVM2KM7:TR?= NHrRfWdUSU6JRWK=
G-401 M2XaXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn\tTWM2OD1yLkG4NlMh|ryP MWLTRW5ITVJ?
EW-16 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEjITnJKSzVyPUCuNVg4PzdizszN MkjjV2FPT0WU
EW-7 M1LK[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHntPWpKSzVyPUCuNVg5QDFizszN NUT4UYgyW0GQR1XS
NCI-H727 NEPCXFNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2PmXWlEPTB;MD6xPVc6PCEQvF2= MoTsV2FPT0WU
LCLC-97TM1 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXzZNoQyUUN3ME2wMlIxQTV3IN88US=> MX\TRW5ITVJ?
NCI-H650 NV75UlJwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1\IVWlEPTB;MD6yNVM5PCEQvF2= NIrW[mxUSU6JRWK=
NCI-H2122 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWfJR|UxRTBwMkOyPVkh|ryP NHnCbVJUSU6JRWK=
SK-N-DZ MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV7JR|UxRTBwMkO2PVgh|ryP M1HRRnNCVkeHUh?=
HT-29 M4nubGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{\FUWlEPTB;MD6yOFI1QCEQvF2= MoLLV2FPT0WU
LB771-HNC MlLyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEP1PZBKSzVyPUCuNlU6OTVizszN MUXTRW5ITVJ?
HT-144 M4XH[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{\lXmlEPTB;MD6yOlE6OSEQvF2= NF7pRW9USU6JRWK=
LAN-6 MmS5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF7LSG1KSzVyPUCuNlY{PDhizszN MmnYV2FPT0WU
EW-18 M1HCWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX7le5B7UUN3ME2wMlI4ODBzIN88US=> M1i5[HNCVkeHUh?=
LS-1034 M{HaV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NETocm9KSzVyPUCuNlcyOzJizszN M1nyeHNCVkeHUh?=
EW-11 NYro[YVJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4n6OGlEPTB;MD6yPFQ{OiEQvF2= NV64OJdLW0GQR1XS
SNU-C1 MmnRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYnJR|UxRTBwMkmzNVMh|ryP MnnyV2FPT0WU
RS4-11 Ml:wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIrReVlKSzVyPUCuN|M4PThizszN MXrTRW5ITVJ?
ES4 MlfxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXHJR|UxRTBwNEGwN|gh|ryP MnH0V2FPT0WU
COLO-320-HSR MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnfHTWM2OD1yLkSxN|Y5KM7:TR?= MmS3V2FPT0WU
NB10 NFT3OHBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1fuTGlEPTB;MD60OVQ{PyEQvF2= NV24PJR3W0GQR1XS
BFTC-905 NHnqXW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVjJR|UxRTBwNE[3OVgh|ryP MkTpV2FPT0WU
A375 NHTSPJlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{Xac2lEPTB;MD60O|YyPyEQvF2= M1rNU3NCVkeHUh?=
SJRH30 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYLoV5g3UUN3ME2wMlUxQDJ{IN88US=> NYr2VW8{W0GQR1XS
NOS-1 MmHYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXnJR|UxRTBwNUKyOlch|ryP MYPTRW5ITVJ?
SIG-M5 M4DDfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYnJR|UxRTBwNUO1OVch|ryP MnTHV2FPT0WU
DOK NV2yT25qT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NInCUmZKSzVyPUCuOVU3KM7:TR?= NH2xNGdUSU6JRWK=
NB69 NImzeJdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFPLXIhKSzVyPUCuOVgzPTdizszN M3XOXHNCVkeHUh?=
SK-NEP-1 NY\TT2djT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGjRcnpKSzVyPUCuOlAzOzZizszN Ml\MV2FPT0WU
SK-MM-2 NYnnOnpNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWPJR|UxRTBwNkW0PVEh|ryP NVPZfIxFW0GQR1XS
NCI-H358 M{[wNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEnzTW5KSzVyPUCuOlcxQDJizszN M1jPc3NCVkeHUh?=
RH-1 NIf6TXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NE\MTlBKSzVyPUCuO|Q5PTlizszN MXjTRW5ITVJ?
NH-12 NXnoTYF4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkLjTWM2OD1yLke2NFQ3KM7:TR?= MYjTRW5ITVJ?
TE-12 NYq3UFZoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{fMTmlEPTB;MD63OlQ5PiEQvF2= NI\2VppUSU6JRWK=
COLO-668 NUD1cIZ1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUHvNpRSUUN3ME2wMlg1PjZ4IN88US=> NGnSdIdUSU6JRWK=
PANC-08-13 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXLJ[FF3UUN3ME2wMlg3Ozd5IN88US=> MVvTRW5ITVJ?
HCC2998 NWeySlE4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2fOT2lEPTB;MD64PFI3OyEQvF2= MoGwV2FPT0WU
ABC-1 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIXYRpBKSzVyPUCuPVA{PTJizszN Mn;CV2FPT0WU
ES6 NXP0fIxwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWjKfZV7UUN3ME2wMlkyODZ4IN88US=> NIL1RlJUSU6JRWK=
SNU-387 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mkn0TWM2OD1yLkm5N|k{KM7:TR?= MorEV2FPT0WU
CMK MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmfETWM2OD1yLkm5PVI6KM7:TR?= NV76TJN3W0GQR1XS
SJSA-1 MlKzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVTJR|UxRTFwMEO2OVMh|ryP NVKwN5RLW0GQR1XS
SIMA NXfobnFQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHvXXphKSzVyPUGuNFY5OjVizszN NF\ldndUSU6JRWK=
ES3 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF:5Z2tKSzVyPUGuNVIzQTdizszN M37qdHNCVkeHUh?=
IGROV-1 M1LUe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2rJ[GlEPTB;MT6xOVQ1PCEQvF2= NULEPZROW0GQR1XS
MEL-JUSO NXjr[mNxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlrSTWM2OD1zLkG1O|U6KM7:TR?= M13L[HNCVkeHUh?=
T84 MlfRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHXiXYJKSzVyPUGuNlA6OTRizszN MYXTRW5ITVJ?
CAL-85-1 Mni0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUjtW|BJUUN3ME2xMlI{OTN6IN88US=> NWXGUml[W0GQR1XS
RD MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmfhTWM2OD1zLkK2OFU2KM7:TR?= NIjISmxUSU6JRWK=
TE-8 NXzC[ZlxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn7BTWM2OD1zLkOxOFYzKM7:TR?= M2PHSXNCVkeHUh?=
L-363 NFr2TWZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYfJR|UxRTFwM{SyNFgh|ryP NHG4XIxUSU6JRWK=
EKVX NXHXSXB7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoCyTWM2OD1zLkO0OVY5KM7:TR?= M3TY[XNCVkeHUh?=
SK-MEL-3 NXPFUVBtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1LiZmlEPTB;MT60PFU2PiEQvF2= MWjTRW5ITVJ?
TGBC24TKB MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnHZTWM2OD1zLkWwNVk{KM7:TR?= NWizd5JDW0GQR1XS
NCI-H1770 NIW5OYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml7iTWM2OD1zLkWxNVE{KM7:TR?= NVX2d4xKW0GQR1XS
HuH-7 M4\QU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3vtOWlEPTB;MT62NFA6QCEQvF2= M{jSbnNCVkeHUh?=
HL-60 M4S5cmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWDUWGU2UUN3ME2xMlY3QTJ6IN88US=> MWPTRW5ITVJ?
TE-1 NUC5PXhFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2LmV2lEPTB;MT63NFk1PSEQvF2= NYTyN5dGW0GQR1XS
LC-2-ad Ml;vS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoDuTWM2OD1zLkezPFg4KM7:TR?= M{XGTnNCVkeHUh?=
LB647-SCLC NXOyOFlDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXHQdXNUUUN3ME2xMlc3PTh|IN88US=> NVjHPJZNW0GQR1XS
NCI-H2171 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYXJR|UxRTFwN{e3NVYh|ryP MnjJV2FPT0WU
SK-PN-DW NFvGb|FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlWxTWM2OD1zLkmxNlk5KM7:TR?= MWrTRW5ITVJ?
MC-IXC NHi3OWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVnpWItxUUN3ME2xMlk5QThizszN M3LvO3NCVkeHUh?=
LS-513 NYPod|c6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnPHTWM2OD1{LkC1N|A2KM7:TR?= MULTRW5ITVJ?
EW-3 NYD4S4htT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWLJR|UxRTJwMEm4OFQh|ryP NYH1e4NkW0GQR1XS
OPM-2 NYfMTIk2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYLacHV7UUN3ME2yMlExOiEQvF2= Ml7WV2FPT0WU
LP-1 M1XKTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoHyTWM2OD1{LkK1PFA4KM7:TR?= MUTTRW5ITVJ?
LU-134-A M{fqS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2r4e2lEPTB;Mj6yO|ch|ryP MmPZV2FPT0WU
CP66-MEL MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{nLZ2lEPTB;Mj6yPVAyPCEQvF2= NHO2TXVUSU6JRWK=
HCC1143 NIPWdYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVzJR|UxRTJwNEWzOlgh|ryP Ml3SV2FPT0WU
LOXIMVI Ml[yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWC1bWZUUUN3ME2yMlYxOjFizszN M1XwcXNCVkeHUh?=
TE-10 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1\wUmlEPTB;Mj63NFg{QCEQvF2= M4LrNHNCVkeHUh?=
NCI-H1882 MmHLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVvBRZFEUUN3ME2yMlc2OjJ5IN88US=> MVTTRW5ITVJ?
CHP-126 NIPXe5JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFLKUmdKSzVyPUKuO|Y{OTdizszN NFjEXWxUSU6JRWK=
NCI-H1623 NGfFOlBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVHJR|UxRTJwOUKwNlQh|ryP MV7TRW5ITVJ?
GB-1 M4HYb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXjyXXJ3UUN3ME2yMlk{PDB2IN88US=> NYHYbZNmW0GQR1XS
RCC10RGB M{D6S2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoLlTWM2OD1{Lkm1NlgyKM7:TR?= M2\XbHNCVkeHUh?=
NCI-H2141 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFzIbXFKSzVyPUKuPVY5QTZizszN MUfTRW5ITVJ?
GI-ME-N NH[xe2dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVHLPYFIUUN3ME2zMlAxPTZ3IN88US=> NEDMOItUSU6JRWK=
NCI-H526 MkHXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEDEZoJKSzVyPUOuNFQxQDVizszN NWrYUGQ6W0GQR1XS
NCI-H747 MnL1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF3odJJKSzVyPUOuNFQ6QTJizszN NXvvWXNVW0GQR1XS
SNU-423 NY\ENnhmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2fGfWlEPTB;Mz6yNFMyOyEQvF2= NH;YWZBUSU6JRWK=
A427 NELKV3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEXWTWZKSzVyPUOuNlU3QTlizszN NHvmfYxUSU6JRWK=
CAL-12T M4W1Nmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYTJR|UxRTNwNEC3NVMh|ryP MmTsV2FPT0WU
LU-99A MlfRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{\ETWlEPTB;Mz60O|ExPSEQvF2= MlzJV2FPT0WU
MS-1 NH65NG5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH;EXVlKSzVyPUOuOVM1OjlizszN M1H6OnNCVkeHUh?=
SK-LU-1 NXvzU5o3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnTyTWM2OD1|Lke2Nlk2KM7:TR?= MkHFV2FPT0WU
SW837 NGHnc3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX\2eZdXUUN3ME2zMlc3OzN|IN88US=> MoPTV2FPT0WU
ES8 M2j3fWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUnnb3h5UUN3ME2zMlg{QDd5IN88US=> NWHkV|FRW0GQR1XS
MZ2-MEL M2XZV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{\Pc2lEPTB;Mz65NlA5PiEQvF2= MUTTRW5ITVJ?
TGW MoPNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmXmTWM2OD12LkCxN|EyKM7:TR?= Ml3jV2FPT0WU
GP5d M1fYemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUG0XHA{UUN3ME20MlA2OzZ{IN88US=> NXLpcXlDW0GQR1XS
BB49-HNC NWrQfot{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYHISIVKUUN3ME20MlE2OjF|IN88US=> NFryWJdUSU6JRWK=
NB13 M4nlS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4nBWmlEPTB;ND6yOlg5PyEQvF2= NELadY5USU6JRWK=
NTERA-S-cl-D1 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlrFTWM2OD12LkK4OlE2KM7:TR?= NYq2S48xW0GQR1XS
NCI-H1648 NF7He5RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUOxSmFGUUN3ME20MlI6QDF7IN88US=> Ml\QV2FPT0WU
LCLC-103H Moq0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1\O[mlEPTB;ND6zNlE6PSEQvF2= MlfuV2FPT0WU
LS-411N M1m4c2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3zLSGlEPTB;ND60OFg5PSEQvF2= MXXTRW5ITVJ?
NCI-H1092 MnLmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX7JR|UxRTRwNEW2PFch|ryP MW\TRW5ITVJ?
PANC-10-05 NHHodXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWDJR|UxRTRwNkm4OEDPxE1? MXrTRW5ITVJ?
DK-MG MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NETEUI5KSzVyPUSuPFA6OzNizszN MVrTRW5ITVJ?
OVCAR-5 NWGzW5M5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYfNc4tSUUN3ME20MlgyOjJ4IN88US=> MULTRW5ITVJ?
CAL-39 M1TwfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIrpVWRKSzVyPUSuPFc3PyEQvF2= MXTTRW5ITVJ?
TE-441-T NV7Qb5FRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUHJR|UxRTRwOUC1N|ch|ryP NF\4ZmpUSU6JRWK=
MOLT-16 MnPvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3uyN2lEPTB;ND65OVI2OyEQvF2= Mn7PV2FPT0WU
MCF7 NVnvcGFRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVvrbW9JUUN3ME21MlE1PTF5IN88US=> MVHTRW5ITVJ?
CAPAN-1 NEn5UGJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoP5TWM2OD13LkK1O|A4KM7:TR?= M{[0XHNCVkeHUh?=
PSN1 MljKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXriclhpUUN3ME21MlI4OjN3IN88US=> NVjzZnl[W0GQR1XS
NCI-H292 MmPnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGnsWIZKSzVyPUWuN|AxPDRizszN M4XYcnNCVkeHUh?=
CPC-N Ml7wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml3vTWM2OD13LkO5OFE6KM7:TR?= M3PvTXNCVkeHUh?=
DoTc2-4510 MmrES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnjhTWM2OD13LkS1N|cyKM7:TR?= NH3VS3hUSU6JRWK=
LB1047-RCC MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH;SUopKSzVyPUWuOVU6OzNizszN NV7OZ5ZsW0GQR1XS
MHH-ES-1 NYXHOXNXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkPtTWM2OD13LkW5PVA4KM7:TR?= MXzTRW5ITVJ?
NMC-G1 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVzJR|UxRTVwN{CyNlch|ryP MnXZV2FPT0WU
SW1710 NFLYbI5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYDJR|UxRTVwN{S3OVEh|ryP M3fvUnNCVkeHUh?=
YAPC MnHpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYDnS|B1UUN3ME21Mlc3OjBzIN88US=> NUKyN2U{W0GQR1XS
22RV1 MoLzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWTJR|UxRTVwOECwNVkh|ryP MW\TRW5ITVJ?
COLO-679 MmThS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXTJR|UxRTVwOEi5OFgh|ryP M2TvTXNCVkeHUh?=
TCCSUP NX3FVFFLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkjETWM2OD13LkmzNlU6KM7:TR?= M3;6WXNCVkeHUh?=
C2BBe1 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYTJR|UxRTVwOUO5O{DPxE1? NUPtR|FUW0GQR1XS
TE-15 NWXHV|J6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmDPTWM2OD14LkC2OlA2KM7:TR?= NFy3fWJUSU6JRWK=
SCLC-21H MkWzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH;md4tKSzVyPU[uNVA5PDNizszN MWLTRW5ITVJ?
EoL-1-cell MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NU\5OphGUUN3ME22MlE3PTZ|IN88US=> NXSzdpVEW0GQR1XS
NKM-1 NGfFPFNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIOxWINKSzVyPU[uNVY4OSEQvF2= MYnTRW5ITVJ?
NCI-H1304 MkLBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWrJR|UxRTZwMke0Nlgh|ryP M3W0fnNCVkeHUh?=
NB6 Mm\jS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXfJR|UxRTZwMkm2NlIh|ryP NUTwdnplW0GQR1XS
NALM-6 NYHQSYwzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3LHTWlEPTB;Nj6zN|I{KM7:TR?= MmLtV2FPT0WU
NCI-H522 NF\ISWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX[yXW1tUUN3ME22MlM{OzB4IN88US=> MV7TRW5ITVJ?
MV-4-11 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmPFTWM2OD14LkO3NFc6KM7:TR?= MX;TRW5ITVJ?
LB2241-RCC M1rZeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVWwSXdvUUN3ME22MlM5PjZ5IN88US=> NYr4e|dbW0GQR1XS
NCI-H1417 NFjUfVJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX7JR|UxRTZwNEC4OFch|ryP NXfKcmZYW0GQR1XS
HT-1197 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYe1O4t{UUN3ME22MlU4OTJ{IN88US=> NXPHUXZjW0GQR1XS
P30-OHK NHjlU3BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWjJR|UxRTZwNkK3O{DPxE1? NFPNWpZUSU6JRWK=
ALL-PO MnPNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXLTVpdwUUN3ME22MlcyQTF4IN88US=> NHPtcHhUSU6JRWK=
OVCAR-4 NUnnV3hPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXzJR|UxRTZwN{W0NFUh|ryP MYrTRW5ITVJ?
HCC2157 NGOyW|JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVjZRmh7UUN3ME22Mlc4PDd3IN88US=> MnfrV2FPT0WU
NCI-H838 NG\mUoZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn[wTWM2OD14Lkm2OFkh|ryP NH74eFVUSU6JRWK=
NCI-H1299 M{PMWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4DjemlEPTB;Nj65O|A6KM7:TR?= NV\H[ldWW0GQR1XS
SW954 NGHRbItIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnzKTWM2OD15LkKwNFY5KM7:TR?= M1n5[XNCVkeHUh?=
NCI-H441 MmnKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYW2N|c6UUN3ME23MlM1ODZ3IN88US=> NIG0dJpUSU6JRWK=
SK-MEL-2 NHuwXlZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{fjc2lEPTB;Nz60PFM4OyEQvF2= Moj0V2FPT0WU
KARPAS-45 NWfUNG9CT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFLoOYtKSzVyPUeuOlU6OjlizszN MXHTRW5ITVJ?
CAL-54 NFr5ZmtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{jZXWlEPTB;Nz64Nlk4PyEQvF2= NIKwZYtUSU6JRWK=
KYSE-180 MonmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXjWRW4{UUN3ME23Mlg5QTRzIN88US=> NVPqe2M6W0GQR1XS
NCI-H187 MkTXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIfPUGdKSzVyPUeuPVU6PDdizszN MYfTRW5ITVJ?
RT-112 M3jwWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV;JR|UxRThwMEm2O|ch|ryP NFLw[JNUSU6JRWK=
NCI-H1437 NI[zbIpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmHQTWM2OD16LkC5O|k2KM7:TR?= MlO4V2FPT0WU
SNU-449 NX\SZYg1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUC1NIdXUUN3ME24MlI5Ojd{IN88US=> M2e0cXNCVkeHUh?=
HCC1187 NXT0[FJYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX\Dc4tzUUN3ME24MlI6OzlzIN88US=> Ml;pV2FPT0WU
NCI-H2030 NEnhUnJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MY\JR|UxRThwM{e3NVQh|ryP M4PLdXNCVkeHUh?=
HuO-3N1 M1nEb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4\QRmlEPTB;OD6zO|g1PCEQvF2= NF3uUoRUSU6JRWK=
COLO-792 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFjpdJNKSzVyPUiuOFE2OjdizszN NGXWO4tUSU6JRWK=
MIA-PaCa-2 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV3JR|UxRThwOEW1NFgh|ryP NInZPW1USU6JRWK=
SK-N-FI M2rhNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MknITWM2OD17LkC0NlUh|ryP NHPuV3VUSU6JRWK=
MMAC-SF MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFnRRlNKSzVyPUmuNFk4PTFizszN MYfTRW5ITVJ?
NCI-H28 NUDoW3BlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWHJR|UxRTlwMUC0Olkh|ryP NEL4PYtUSU6JRWK=
ETK-1 MkD6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4rTUWlEPTB;OT6yPVk4PCEQvF2= MoqwV2FPT0WU
NCI-H1993 NWrYdm03T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXPRRld4UUN3ME25MlQ1OjZzIN88US=> M{[4[HNCVkeHUh?=
no-11 NXn1U3ltT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX\lXnYxUUN3ME25MlQ4OTJizszN MnvnV2FPT0WU
ChaGo-K-1 NF\4UmNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFfa[mlKSzVyPUmuOVE2QDNizszN NVjQ[WdEW0GQR1XS
NCCIT MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MULJR|UxRTlwNUOxOlkh|ryP M3nGSHNCVkeHUh?=
SAS MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3HscmlEPTB;MUCuNlQ5KM7:TR?= M3\OW3NCVkeHUh?=
A673 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1;TUWlEPTB;MUCuN|cxPCEQvF2= NFXQbmlUSU6JRWK=
NCI-H1522 Mm\sS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4LjNGlEPTB;MUCuN|cxPyEQvF2= NIO1[3hUSU6JRWK=
NCI-H810 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWfwZoZVUUN3ME2xNE4{QTB5IN88US=> MULTRW5ITVJ?
IST-MES1 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX3JR|UxRTFyLkS1OlQh|ryP M{LnO3NCVkeHUh?=
GR-ST MmLYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVrJR|UxRTFyLkWwNlQh|ryP MVLTRW5ITVJ?
SUP-T1 M1TaOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF\hdHFKSzVyPUGwMlc{OTdizszN M3n1OnNCVkeHUh?=
NB5 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2XFfWlEPTB;MUCuPVAzOiEQvF2= MXTTRW5ITVJ?
MZ1-PC M4\QdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV3PW|RtUUN3ME2xNE46PTdzIN88US=> M{WxN3NCVkeHUh?=
SK-CO-1 M4H4S2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYXJTFZVUUN3ME2xNE46QTNzIN88US=> Mn:zV2FPT0WU
Capan-2 NG\O[VJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIPnR2xKSzVyPUGxMlMyQThizszN MnrBV2FPT0WU
697 MoLXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkCxTWM2OD1zMT62O|U4KM7:TR?= NGLGTZdUSU6JRWK=
REH M2OzTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYDJR|UxRTFzLke0OVEh|ryP M4\CR3NCVkeHUh?=
GI-1 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUfJR|UxRTFzLki2NVUh|ryP M2XGOnNCVkeHUh?=
BB65-RCC NV31PG5zT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVjJR|UxRTF{LkC5NVYh|ryP NGrWSI1USU6JRWK=
NCI-H1651 M2XaS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXzJR|UxRTF{LkK0O|gh|ryP M4DYVHNCVkeHUh?=
NCI-H1618 MnzsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1vCV2lEPTB;MUKuN|k4PiEQvF2= NFnrWnlUSU6JRWK=
NCI-H2081 NF7YUWRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEfubJRKSzVyPUGyMlYyPDFizszN NXLIZWRWW0GQR1XS
GCIY MnnXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MULJR|UxRTF{LkeyNVMh|ryP MmnBV2FPT0WU
NY MoX2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIftTIpKSzVyPUGzMlA3PDNizszN NIi5WXpUSU6JRWK=
PANC-03-27 NFv2R|hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV;G[XhkUUN3ME2xN{4xQDB5IN88US=> NHXkZ2pUSU6JRWK=
BHY MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYTuTYV4UUN3ME2xN{4zOTJzIN88US=> Ml;BV2FPT0WU
SK-OV-3 NH7tcIVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3HaeGlEPTB;MUOuN|c3OyEQvF2= MoDsV2FPT0WU
5637 MnfKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWjJR|UxRTF|Lke3OVkh|ryP MnHYV2FPT0WU
LC-1F MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2TsUWlEPTB;MUSuNFM2PiEQvF2= NGjoZVBUSU6JRWK=
SNB75 Ml[zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MY\JR|UxRTF2LkCzPFMh|ryP NFrpN4hUSU6JRWK=
CHP-212 NVfNT4FqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWXJR|UxRTF2LkC0OlQh|ryP NH\PVGRUSU6JRWK=
HT-1376 NIDn[mlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFHqeGhKSzVyPUG0MlEyOjZizszN M2r6XXNCVkeHUh?=
MONO-MAC-6 NGLHcWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{XmdmlEPTB;MUSuNVUxOiEQvF2= NFTrVXRUSU6JRWK=
CA46 M3nrXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEm2OIJKSzVyPUG0MlE5OjdizszN NEO1NYRUSU6JRWK=
SCC-15 M2XrbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVyyeGR6UUN3ME2xOE42PTh|IN88US=> NYqxPI1FW0GQR1XS
ATN-1 M3SzSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXHJR|UxRTF2Lk[2Nlch|ryP NEXqdVRUSU6JRWK=
NCI-H2405 MoHnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoLJTWM2OD1zND64NVU4KM7:TR?= MVPTRW5ITVJ?
NCI-H716 NFvVbmFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV7pNXZwUUN3ME2xOE45PDl|IN88US=> NHTt[2hUSU6JRWK=
SW620 NHjEboZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWnJR|UxRTF2LkmwNVQh|ryP NU\4VVVnW0GQR1XS
NCI-H226 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWj2fYE1UUN3ME2xOE46ODh3IN88US=> NFjQOZVUSU6JRWK=
SW962 MmPYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4C2NWlEPTB;MUSuPVQ{OiEQvF2= Ml\5V2FPT0WU
KYSE-150 MmHoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkPnTWM2OD1zND65OVUh|ryP M1m3eXNCVkeHUh?=
OCUB-M M1juRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnO4TWM2OD1zND65PFg{KM7:TR?= MnPyV2FPT0WU
ES7 NGnhW2dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGTQe|dKSzVyPUG1MlA6QDRizszN MmDWV2FPT0WU
SW1463 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVzJR|UxRTF3LkSyNlMh|ryP M4H0d3NCVkeHUh?=
CAKI-1 NIXGO5FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4XPTWlEPTB;MUWuOVM1PiEQvF2= MVHTRW5ITVJ?
MKN28 M2P0XWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYHJR|UxRTF3LkW0O|kh|ryP NHfwemdUSU6JRWK=
SW13 NYqzUGtzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVjCNJJSUUN3ME2xOU43OThizszN M3T4UHNCVkeHUh?=
A3-KAW NX76OoE5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlfKTWM2OD1zNT65Olk4KM7:TR?= MomxV2FPT0WU
LU-65 NGDyNnFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUHJR|UxRTF3Lkm3Olgh|ryP NXjTTWhuW0GQR1XS
Calu-1 M4PYe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVHzUI01UUN3ME2xOk4xOzZ6IN88US=> M{XUUXNCVkeHUh?=
ST486 NXXNPYRuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoXMTWM2OD1zNj6wOFMyKM7:TR?= MoHxV2FPT0WU
BB30-HNC MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYnJR|UxRTF4LkGyOFYh|ryP NUC2WGtiW0GQR1XS
EGI-1 MkXzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2SyfGlEPTB;MU[uOFQ3KM7:TR?= MonaV2FPT0WU
SH-4 NX\qNGcxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUPJR|UxRTF4LkS3N|Eh|ryP MULTRW5ITVJ?
MN-60 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX\JR|UxRTF5LkKyPVch|ryP M1\CU3NCVkeHUh?=
MPP-89 M4HvOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYLNbVhqUUN3ME2xO{4zPDV7IN88US=> M1nNbHNCVkeHUh?=
A2780 Moi0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmCzTWM2OD1zNz60NVM6KM7:TR?= NYDM[5hCW0GQR1XS
Daoy MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1PVT2lEPTB;MUeuOFY6PSEQvF2= MX7TRW5ITVJ?
NCI-H2126 Mk\MS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFzydG1KSzVyPUG3MlQ4PzFizszN NXnpRYhOW0GQR1XS
NCI-H1563 MnvsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUjJR|UxRTF5LkS5NVch|ryP Mn\1V2FPT0WU
8-MG-BA NFezTJNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3nzWWlEPTB;MUeuOlY1QCEQvF2= M1PLeHNCVkeHUh?=
786-0 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWjlSmd3UUN3ME2xO{45OzV|IN88US=> NYnBRnY3W0GQR1XS
AM-38 NVGzNXpuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mkf4TWM2OD1zNz65N|A3KM7:TR?= Mn:yV2FPT0WU
COLO-824 M4DSV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFHhdVFKSzVyPUG4MlQ1OzZizszN M1:5TnNCVkeHUh?=
SK-MEL-30 M1PySGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYnJR|UxRTF6LkWwPFIh|ryP M1izOHNCVkeHUh?=
CESS M{fqUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M13McGlEPTB;MUiuO|YxQSEQvF2= MVLTRW5ITVJ?
BL-70 NXn5NW9sT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkfJTWM2OD1zOD64NVU3KM7:TR?= Mlq4V2FPT0WU
NCI-H2170 M{LtTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF\FRpVKSzVyPUG4MlkyPzlizszN NFK5Zm9USU6JRWK=
HT-3 NH22PZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXTyW2QxUUN3ME2xPE46QDNizszN M3Huc3NCVkeHUh?=
BOKU NXPyd3JyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2DHZmlEPTB;MUmuNFM5OSEQvF2= MUfTRW5ITVJ?
HPAF-II M2PpS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M33VbWlEPTB;MUmuN|AyPSEQvF2= NGe5PHBUSU6JRWK=
KGN NEX5eZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX7JR|UxRTF7LkS3OlUh|ryP NIf6Z2tUSU6JRWK=
MC-CAR NHHxeYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH;5SVJKSzVyPUG5MlY{OTNizszN MlHpV2FPT0WU
BHT-101 NGL1WYpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{\jZmlEPTB;MUmuO|c4KM7:TR?= MoDoV2FPT0WU
SW1783 NFzBcplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVXYfZBbUUN3ME2xPU44QDB4IN88US=> MVHTRW5ITVJ?
KP-N-YN NF7kbohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{PqemlEPTB;MkCuNFI3OiEQvF2= Mn7rV2FPT0WU
LU-165 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4OzUmlEPTB;MkCuOVU4OSEQvF2= MX3TRW5ITVJ?
GOTO MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF\Yd4pKSzVyPUKwMlY1PTFizszN MlrxV2FPT0WU
EFM-19 NWrNcpRrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoPDTWM2OD1{MT6wO|E3KM7:TR?= MVfTRW5ITVJ?
CTV-1 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUDPeGQ3UUN3ME2yNU4yODV2IN88US=> MmPhV2FPT0WU
HEL M3fuS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn;TTWM2OD1{MT60NlE3KM7:TR?= MVTTRW5ITVJ?
SNU-C2B NHX0ZodIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEjl[VZKSzVyPUKxMlQzPiEQvF2= MoHXV2FPT0WU
ECC4 NHfaSXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkHUTWM2OD1{MT63NFch|ryP MYTTRW5ITVJ?
NEC8 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{HjOWlEPTB;MkGuPFM3QCEQvF2= NGDQT4VUSU6JRWK=
KMOE-2 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH\oZnBKSzVyPUKxMlg6OjFizszN MX;TRW5ITVJ?
NCI-H524 NInIW5ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MULJR|UxRTJ{LkC4NFgh|ryP MWXTRW5ITVJ?
WSU-NHL MlLiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWHJR|UxRTJ{LkG1O|ch|ryP NH:5Z|dUSU6JRWK=
SF126 M2jiUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmHkTWM2OD1{Mj6yOFY6KM7:TR?= NFnoWoRUSU6JRWK=
HOP-92 MkL0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml[3TWM2OD1{Mj6zNVY4KM7:TR?= MoGzV2FPT0WU
CTB-1 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4fmRWlEPTB;MkKuOFY4PyEQvF2= MnPZV2FPT0WU
KYSE-270 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGrJPFlKSzVyPUKyMlk{PTdizszN NX;MNmdwW0GQR1XS
SK-MEL-24 NFrERmRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVPhdpc{UUN3ME2yN{4yQDdizszN NHzBd3ZUSU6JRWK=
Calu-3 NF7nNJlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M33xfGlEPTB;MkOuNlEzQCEQvF2= NUjrdHRzW0GQR1XS
GAMG MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M37QU2lEPTB;MkOuNlM3PyEQvF2= MVrTRW5ITVJ?
SW1573 NELXPXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUXMdHRtUUN3ME2yN{44PDF3IN88US=> MUfTRW5ITVJ?
MHH-NB-11 NIrMTGNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVf4eoxHUUN3ME2yOE4xOTl2IN88US=> NFy1NXFUSU6JRWK=
TK10 NULNZo1oT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIjGd2NKSzVyPUK0MlUxOTNizszN Ml;tV2FPT0WU
LB373-MEL-D MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHzEXVZKSzVyPUK0MlYxPjRizszN NVXrVIVwW0GQR1XS
KALS-1 NH20VZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUnn[nN2UUN3ME2yOE44OzJ5IN88US=> NVLKOoF1W0GQR1XS
HUTU-80 NX3XN4lHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml7BTWM2OD1{NT64NFMzKM7:TR?= M4nQbnNCVkeHUh?=
HuP-T3 MnLoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVjJR|UxRTJ4LkG2O|Qh|ryP NFHFO41USU6JRWK=
OE19 MkTQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGP5XZhKSzVyPUK2MlIyPTNizszN M2To[XNCVkeHUh?=
J82 NU\XVnRQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX3uTGNlUUN3ME2yOk4zPDdzIN88US=> NV72b5Z{W0GQR1XS
DU-4475 NUfuZod{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NU\KRnJZUUN3ME2yOk4{QDF7IN88US=> MX;TRW5ITVJ?
DMS-53 MlrIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn3BTWM2OD1{Nj61NVM5KM7:TR?= NVn1WpJ5W0GQR1XS
COLO-741 M2mxfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVXpbGZYUUN3ME2yOk45OzR2IN88US=> MYnTRW5ITVJ?
SW48 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV\pXVhRUUN3ME2yOk45QDJizszN NGf0XHVUSU6JRWK=
IGR-1 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEPRNpFKSzVyPUK2Mlk{OzRizszN MXfTRW5ITVJ?
639-V M3PX[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3\6UGlEPTB;MkeuNFI1PSEQvF2= NGjpOHhUSU6JRWK=
LK-2 NGXqR|JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn7sTWM2OD1{Nz60NVQyKM7:TR?= NYL3VGNuW0GQR1XS
NCI-H2347 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWjJR|UxRTJ5Lkm2PVkh|ryP MlPVV2FPT0WU
NCI-H2228 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWnJR|UxRTJ6LkC5NFUh|ryP MWPTRW5ITVJ?
LS-123 NELMcWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUjJR|UxRTJ6LkGyOlIh|ryP NETmTYNUSU6JRWK=
U031 NYTCZWFxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M17UXmlEPTB;MkiuNlUzKM7:TR?= MnTIV2FPT0WU
NCI-H1792 NH;q[nRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MU\JR|UxRTJ6LkS3NlEh|ryP M1jaPHNCVkeHUh?=
NCI-H2087 M3j2NGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEPBcnZKSzVyPUK4Mlc2PTJizszN NFHEcI5USU6JRWK=
NCI-H2342 M3XR[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV7iNGNHUUN3ME2yPU42OjB6IN88US=> M3HFXHNCVkeHUh?=
SW626 NUP2eGs1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NITNXZRKSzVyPUK5Mlc2PiEQvF2= NHXHO3ZUSU6JRWK=
LB2518-MEL NEfWe3hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGLpe|NKSzVyPUK5MlgyPSEQvF2= MX\TRW5ITVJ?
RXF393 Mnn4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlvHTWM2OD1|MD6wPVUzKM7:TR?= M{nO[3NCVkeHUh?=
LC4-1 Ml;xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoDYTWM2OD1|MD6zNFkzKM7:TR?= M3n4NHNCVkeHUh?=
NCI-H1694 NV20cHBDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlfRTWM2OD1|MD62OlI1KM7:TR?= NGGy[VRUSU6JRWK=
K5 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWnJR|UxRTNyLkm3NFIh|ryP NXXObFlbW0GQR1XS
HDLM-2 NW\HWHVpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2rNbWlEPTB;M{CuPVczPSEQvF2= MUPTRW5ITVJ?
BCPAP MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3LqSGlEPTB;M{GuPFM4QSEQvF2= MVjTRW5ITVJ?
BC-3 NVvze2d6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWPX[oZ{UUN3ME2zNk4yPDB|IN88US=> Mln3V2FPT0WU
LB996-RCC M37qRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH35cYhKSzVyPUOyMlI{PThizszN NUDrZ5ZQW0GQR1XS
NCI-H2009 MorxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYTJR|UxRTN{LkS5PFEh|ryP NEPUVFFUSU6JRWK=
HTC-C3 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mo\aTWM2OD1|Mz63OVE6KM7:TR?= NWnVOFdzW0GQR1XS
LAMA-84 NYriSXR{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NW\nWFRiUUN3ME2zOE41PDB5IN88US=> MmX1V2FPT0WU
CCRF-CEM NVrFNJhWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3\mNGlEPTB;M{SuOVcyPSEQvF2= Ml20V2FPT0WU
AN3-CA NYTtOXpsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXnQeYdVUUN3ME2zOU4xPTZ6IN88US=> NGnXe4hUSU6JRWK=
NCI-H1734 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlLlTWM2OD1|NT6yOVYyKM7:TR?= MmXEV2FPT0WU
Ca-Ski Ml:xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1[3dmlEPTB;M{WuOFExOSEQvF2= MXPTRW5ITVJ?
U-266 NWm1PIhMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1i1O2lEPTB;M{WuOlEyPCEQvF2= NV7JNGZpW0GQR1XS
SBC-5 NFvZVGVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF;1d2lKSzVyPUO1Mlc4QDFizszN M1HtTXNCVkeHUh?=
GT3TKB M1;LeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn:yTWM2OD1|Nz6xNVUh|ryP NVfTS5VQW0GQR1XS
MDA-MB-175-VII NH61UHdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUPwfFVuUUN3ME2zO{4zOjR6IN88US=> M1\H[3NCVkeHUh?=
PFSK-1 M1O3eWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3fObmlEPTB;M{euNlQ{PSEQvF2= MV;TRW5ITVJ?
IMR-5 NIrPOmRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn3QTWM2OD1|Nz6yOFg4KM7:TR?= M2ntVXNCVkeHUh?=
Daudi MkP6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2PTS2lEPTB;M{euN|U6PyEQvF2= M4HGcHNCVkeHUh?=
A498 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWD1R3BoUUN3ME2zO{44OjF6IN88US=> NYDoblh7W0GQR1XS
SCC-4 MoPLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml\xTWM2OD1|Nz63PFQ{KM7:TR?= M3r6enNCVkeHUh?=
COLO-680N MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmHITWM2OD1|OD6yPFg2KM7:TR?= NH2xRXdUSU6JRWK=
SK-MES-1 NGq5dYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml[wTWM2OD1|OD6zNlE2KM7:TR?= Mnj0V2FPT0WU
SR NXj4eXNpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWDobINVUUN3ME2zPE42PDl3IN88US=> NEXBe|VUSU6JRWK=
LNCaP-Clone-FGC NWLsPFJVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVfuVlVnUUN3ME2zPE42PjN5IN88US=> NFHrXVlUSU6JRWK=
SK-HEP-1 NIe0UmdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3W0V2lEPTB;M{iuO|gzOiEQvF2= MX;TRW5ITVJ?
BPH-1 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoPNTWM2OD1|OD64N|I6KM7:TR?= MnPRV2FPT0WU
NCI-H1755 NFzOW5ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml3FTWM2OD1|OT61PFE4KM7:TR?= MoTjV2FPT0WU
LXF-289 M{DCe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn7rTWM2OD1|OT64NFg1KM7:TR?= M1jYOnNCVkeHUh?=
SW1088 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1n4bGlEPTB;NECuNlExPyEQvF2= MUPTRW5ITVJ?
MOLT-4 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXW5eXdjUUN3ME20NE4zQTBzIN88US=> Mn6yV2FPT0WU
AsPC-1 MlnQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUC1OGZoUUN3ME20NE41PTh|IN88US=> NE[3WZdUSU6JRWK=
HOP-62 M3PYNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVjGRnN3UUN3ME20NE43PTZ6IN88US=> MlnvV2FPT0WU
A172 NFTQcXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M33wcGlEPTB;NECuPFUyOSEQvF2= MUjTRW5ITVJ?
SN12C NHTrToVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3PZdGlEPTB;NECuPVM5PSEQvF2= NHfrOZFUSU6JRWK=
MDA-MB-231 NV3vZYQ5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MW\JR|UxRTRyLkm4PVgh|ryP Ml61V2FPT0WU
RPMI-2650 NX\xWWxkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoL3TWM2OD12MT6xOVk{KM7:TR?= MnftV2FPT0WU
KYSE-140 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4HKNWlEPTB;NEGuPFEzOyEQvF2= M2nBd3NCVkeHUh?=
KINGS-1 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIH4S|FKSzVyPUSyMlQ3QTdizszN M2fpO3NCVkeHUh?=
HSC-3 NFrUemlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX7JR|UxRTR{Lk[2OlEh|ryP NHG5flFUSU6JRWK=
PC-14 NWTGUJY5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGTPWHZKSzVyPUSzMlE5QDJizszN NW\uUHprW0GQR1XS
COR-L105 M4\Rdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV\JR|UxRTR|Lk[1NFIh|ryP M1WwWnNCVkeHUh?=
BE-13 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkHoTWM2OD12ND6yN|cyKM7:TR?= MWrTRW5ITVJ?
NCI-H661 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH\QXplKSzVyPUS0MlI6PThizszN M17zPXNCVkeHUh?=
IST-MEL1 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFK5PVFKSzVyPUS0MlM2QTlizszN M3:ySXNCVkeHUh?=
HCC1806 NFrCUoVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXjJR|UxRTR2LkW4O|Mh|ryP NIO4WIVUSU6JRWK=
COLO-800 M4jTOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXPJR|UxRTR2Lki0OVMh|ryP MV\TRW5ITVJ?
IST-SL2 MnTUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4fUd2lEPTB;NEWuNVI1PyEQvF2= NYTaOpdiW0GQR1XS
8305C M{LLVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoO4TWM2OD12NT6zNFkh|ryP MkjGV2FPT0WU
UACC-62 NGXxSlNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M164OmlEPTB;NE[uNlg4PSEQvF2= MmTzV2FPT0WU
COR-L23 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUjJR|UxRTR5LkG5PUDPxE1? M4T1cnNCVkeHUh?=
EFE-184 MoK3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{D5TGlEPTB;NEeuN|g5KM7:TR?= NGXPOFRUSU6JRWK=
DMS-114 M{jaVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmX4TWM2OD12Nz60NVQ6KM7:TR?= MnHYV2FPT0WU
KYSE-520 NYL1Z3RoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmXOTWM2OD12OD61N|E2KM7:TR?= NHT0NVlUSU6JRWK=
SNG-M M1Hremdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2D2bWlEPTB;NEmuOFM1KM7:TR?= NHP4ZW5USU6JRWK=
A2058 M173Rmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{i5OGlEPTB;NEmuOFg5PSEQvF2= NWr3UHRZW0GQR1XS

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
p-EGFR / EGFR / p-IGF1R / IGF1R / p-IRS1 / IRS1 / p-ERK / ERK / p-AKT / AKT; 

PubMed: 26052929     


Effects of linsitinib on EGFR and IGF1R Signaling Pathways. H1975, AR1, AR2 and AR3 cells were treated with control DMSO or linsitinib (2 and 5 μM) for 24 hours. Cell lysates were subjected to Western blot analysis. IGF1R-IRS-1-AKT phosphorylation was effectively inhibited by linsitinib in afatinib resistance cells whereas IRS-1-AKT phosphorylation was up-regulated by linsitinib in H1975 parental cells.

p-IGF1R / IGF1R / p-mTOR / mTOR ; 

PubMed: 28440057     


Linsitinib inhibits the activation of ERK and PI3K pathways. After treatment of Linsitinib at 0.1 or 1.0 μmol/L for 72 h, the phosphorylation of insulin‐like growth factor‐1 receptor (IGF‐1R), ERK1/2, and AKT/mTOR pathways were analyzed in TE‐13, TE‐1, and KYSE‐510 cell lines by western blot.

cleaved caspase-3 / cleaved PARP; 

PubMed: 28440057     


Reduced apoptosis in Linsitinib-resistant esophageal squamous cell carcinoma cells. After treatment of Linsitinib at 0.1 or 1.0 μmol/L for 72 h, cleaved PARP and activated Caspase‐3 were examined in TE-13, TE-1, and KYSE-510 cells by western blot. Tubulin was used as a loading control.

pSrc(Y416) / Src; 

PubMed: 26515601     


A549, H226Br, and H1975 cells were treated with 1 or 2 μM linsitinib (diluted in RPMI 1640 medium containing 10% FBS) for 12 or 24 h. Before harvest, cells were further stimulated with 10% FBS for 20 min. Cells were lysed with modified RIPA buffer and the protein expression was determined by Western blot analysis.

p-STAT3(Y705) / STAT3 ; 

PubMed: 26041671     


H226B and H460 cells were subject to daily treatment with linsitinib (1 μM) for 1-5 days.

pS6 / S6; 

PubMed: 21257723     


Western blot of NCI-H292 cells following 30 minutes of exposure to OSI-906 shows target inhibition of pIGF-1R and pIR at all doses as well as inhibition of downstream targets pAKT and pS6.

26052929 28440057 26515601 26041671 21257723
Immunofluorescence
FoxO1; 

PubMed: 27535223     


After starvation, control or βIRKO β-cell lines were treated with insulin (10 nm) in combination with high glucose (450 mg/dL), in the presence or absence of PI3K inhibitor LY294002, insulin receptor, and IGF1 receptor dual inhibitor OSI-906, Akt inhibitor MK2206, or MEK1/2 inhibitor U0126 for 30 min.  A, representative pictures of β-cells immunostained for FoxO1 (red) and DAPI (blue). The scale bar indicates 20 μm.

27535223
Growth inhibition assay
Cell viability; 

PubMed: 26136493     


InsR/IGF1R dual inhibitors, OSI-906 and BMS-754807, dose-dependently inhibited T4105 viability.

26136493
In vivo OSI-906 inhibits tumor growth in an IGF-1R-driven xenograft mouse model, with 100% TGI and 55% regression at a dose of 75 mg/kg and 60% TGI and no regression at a dose of 25 mg/kg. OSI-906 administration induces different elimination half-lives of itself in dog, rat and mice, the elimination half-lives are 1.18 hours, 2.64 hours and 2.14 hours, respectively. OSI-906 administration at different single dose once-daily in femal Sprague-Dawley rat and femal CD-1 mouse reveal that the Vmax is not dose-proportional to OSI-906 dose. OSI-906 elevates the blood glucose levels at a dose of 25 mg/kg after 12 days administration. OSI-906 administration at a single dose of 75 mg/kg in IGF-1R-driven full-length human IGF-1R (LISN) xenograft mouse model achieve maximal inhibition of IGF-1R phosphorylation (80%) between 4 and 24 hours with plasma drug concentrations of 26.6-4.77 μM. [1] OSI-906 administered as a single dose of at 60 mg/kg in NCI-H292 xenografts mice inhibits uptake of glucose at 2, 4, and 24 hours post-treatment in vivo. OSI-906 inhibits the growth of tumors in NCI-H292 xenograft mouse model. [2]

Protocol

Kinase Assay:[1]
- Collapse

Protein kinase biochemical assays:

Protein kinase assays are either performed in-house by ELISA-based assay methods (IGF-1R, IR, EGFR and KDR) or at Upstate Inc. by a radiometric method with ATP at 100 µM concentration. In-house ELISA assays use poly(Glu:Tyr) as the substrate bound to the surface of 96-well assay plates and phosphorylation is detected using an antiphosphotyrosine antibody conjugated to horseradish peroxidase. The bound antibody is quantified using ABTS as the peroxidase substrate by measuring absorbance at 405 / 490 nm. All assays use purified recombinant kinase catalytic domains. Recombinant enzymes of human IGF-1R or EGFR are expressed as an NH2-terminal glutathione S-transferase fusion protein in insect cells and are purified in house. IC50 values are determined from the sigmoidal dose–response plot of percent inhibition versus log10 compound concentration. A minimum of three measurements, performed in duplicate, are carried out with in-house assays unless otherwise indicated. OSI-906 at a concentration of 1 µM is profiled versus a panel of kinases using the ProfilerProTM Kinase Selectivity Assay Kit.
Cell Research:[1]
- Collapse
  • Cell lines: MCF7, NCI-H292, Colo-205, HT29, H358, H1703, BxPC3, A673, SW620, DU4475, HepG2 and Hepa-1, RKO 3T3/hulGF-IR and H292 cells
  • Concentrations: 0.02-0.8 μM
  • Incubation Time: 3 days
  • Method: For assays of cell proliferation, cells are seeded into 96-well plates in appropriate media containing FCS 10% and incubated for 3 days in the presence of OSI-906 at various concentrations. Inhibition of cell growth is determined by luminescent quantitation of intracellular ATP content using CellTiterGlo. Data is presented as a fraction of maximal proliferation, calculated by dividing the cellular density in the presence of varying concentrations of OSI-906 by the cellular density of control cells treated with vehicle (DMSO) only.
    (Only for Reference)
Animal Research:[1]
- Collapse
  • Animal Models: IGF-1R-driven full-length human IGF-1R (LISN) xenograft mouse model
  • Formulation: 25 mM tartaric acid
  • Dosages: 25 mg / kg and 75 mg / kg
  • Administration: Orally administrated at once-daily oral dose for 14 days
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 84 mg/mL (199.29 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
5%DMSO+40%PEG300+5%Tween80+50%ddH2O
For best results, use promptly after mixing.
6.25mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 421.49
Formula

C26H23N5O

CAS No. 867160-71-2
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT02546544 Completed Drug: Linsitinib Relapsed Ewing Sarcoma|Refractory Ewing Sarcoma University of Oxford|European Organisation for Research and Treatment of Cancer - EORTC|European Commission|Astellas Pharma Inc|Oxford University Hospitals NHS Trust March 2014 Phase 2
NCT01672736 Terminated Drug: ASP7487 Velcade Dexamethasone Multiple Myeloma University Health Network Toronto|Multiple Myeloma Research Consortium|Astellas Pharma Inc September 2012 Phase 1|Phase 2
NCT01529684 Completed Drug: radio-labeled OSI-906|Drug: OSI-906 Advanced Solid Tumors|Pharmacokinetics of 14C-OSI-906 Astellas Pharma Global Development Inc.|Astellas Pharma Inc March 19 2012 Phase 1
NCT01221077 Completed Drug: OSI-906|Drug: Erlotinib|Drug: Placebo NSCLC|Non Small Cell Lung Cancer Astellas Pharma Inc April 8 2011 Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    Does the inhibitor dissolve in the vehicle (30% PEG400/0.5%Tween 80/5% propylene glycol) or is it a suspension?

  • Answer:

    OSI-906 in 30% PEG400/0.5%Tween 80/5% propylene glycol is a suspension.

IGF-1R Signaling Pathway Map

IGF-1R Inhibitors with Unique Features

Related IGF-1R Products

Tags: buy Linsitinib (OSI-906) | Linsitinib (OSI-906) supplier | purchase Linsitinib (OSI-906) | Linsitinib (OSI-906) cost | Linsitinib (OSI-906) manufacturer | order Linsitinib (OSI-906) | Linsitinib (OSI-906) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID